Skip to content

Study · Randomized controlled trial · n = 20 · 2017

7 results

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.

Frandsen CS, Dejgaard TF, Andersen HU, Holst JJ, Hartmann B, Thorsteinsson B, Madsbad S

Diabetes, obesity & metabolism17 Mar 2017Cited by 30 (Europe PMC)

PMID27868372 (opens in a new tab)DOI10.1111/dom.12830 (opens in a new tab)PepBankPUB-27868372
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, gastric emptying rate changes during hypoglycaemia did not differ between liraglutide and placebo after 12 weeks.

    In plain wordsIn adults with type 1 diabetes, liraglutide did not change how fast the stomach empties during low blood sugar compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in gastric emptying rate
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks of treatment, changes in GE rates did not differ significantly between groups ( P  = .96), with no significant changes from baseline, whether evaluated from AUCs or time to peak.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, glycaemic recovery during hypoglycaemia was similar with liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, recovery from low blood sugar was similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlycaemic recovery from hypoglycaemia
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The secondary endpoints, glycaemic recovery, counter-regulatory hormone responses, systolic blood pressure and GLP-1 and PP responses, were also similar.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, counter-regulatory hormone responses to hypoglycaemia were similar with liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, stress hormone responses to low blood sugar were similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCounter-regulatory hormone responses
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The secondary endpoints, glycaemic recovery, counter-regulatory hormone responses, systolic blood pressure and GLP-1 and PP responses, were also similar.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, systolic blood pressure was similar with liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, systolic blood pressure was similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The secondary endpoints, glycaemic recovery, counter-regulatory hormone responses, systolic blood pressure and GLP-1 and PP responses, were also similar.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, GLP-1 responses were similar with liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, GLP-1 hormone responses were similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGLP-1 response
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The secondary endpoints, glycaemic recovery, counter-regulatory hormone responses, systolic blood pressure and GLP-1 and PP responses, were also similar.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes on insulin, pancreatic polypeptide responses were similar with liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes, pancreatic polypeptide responses were similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changePancreatic polypeptide (PP) response
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The secondary endpoints, glycaemic recovery, counter-regulatory hormone responses, systolic blood pressure and GLP-1 and PP responses, were also similar.
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with type 1 diabetes on insulin, heart rate increased with liraglutide from 69 to 80 beats/min.

    In plain wordsIn adults with type 1 diabetes, liraglutide raised the heart rate from 69 to 80 beats per minute.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate
    Study

    n = 20

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.2 mg once daily · 12 weeksAs given in this study (human).

    Measurements

    Heart rate
    69 beats/min
    baseline
    Heart rate
    80 beats/min
    after liraglutide

    Source sentences

    Summary
    Heart rate increased with liraglutide from 69 ± 4 to 80 ± 5 beats/min ( P  = .02).
    1 context sentence
    Summary · context
    In a 12-week, randomized, double-blind, placebo-controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add-on to insulin treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.